Dublin, April 26, 2019 (GLOBE NEWSWIRE) -- The "Stem Cell Therapies for Cardiovascular and Metabolic Disorders, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Stem Cell Therapies for Cardiovascular & Metabolic Disorders, 2019-2030 report features an extensive study of the current market landscape and the future potential of stem cell therapies in treating the aforementioned clinical conditions. The study includes all stem cell therapies that are being developed for the treatment of cardiovascular and metabolic disorders. In addition, we have provided a list of stem cell therapies being developed for stroke, a condition associated with vasculature in the brain.

Key Topics Covered:

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Stem Cell Therapy
3.2.1. Classification of Stem Cell Therapies by Type of Cells
3.2.1.1. Embryonic Stem Cells
3.2.1.2. Adult Stem Cells
3.2.1.3. Induced Pluripotent Stem Cells
3.2.1.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
3.2.2. Applications of Stem Cell Therapy
3.3. Overview of Cardiovascular Disorders
3.3.1. Key Indications being Investigated for Treatment with Stem Cells
3.4. Overview of Metabolic Disorders
3.4.1. Key Indications being Investigated for Treatment with Stem Cells
3.5. Administration of Stem Cell Therapies
3.6. Challenges Associated with Developing Stem Cell Therapies
3.7. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
4.2.1. Analysis by Target Therapeutic Area
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Source of Stem Cells
4.2.4. Analysis by Type of Stem Cells
4.2.5. Analysis by Stem Cell Lineage
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Target Indication
4.2.7.1. Cardiovascular Disorders
4.2.7.2. Metabolic Disorders
4.2.8. Key Developers
4.2.9. Heptagon Representation: Analysis by Target Indication and Phase of Development of Stem Cell Therapies
4.2.10. Grid Analysis: Target Indications, Phase of Development and Source of Stem Cells
4.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Landscape
4.3.1. Distribution by Focus Area
4.3.2. Distribution by Year of Establishment
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Geographical Location
4.3.5. Mapping Regional Activity
4.3.6. Logo Landscape: Analysis by Size and Target Therapeutic Area
4.4. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Additional Information
4.4.1. Information on Dosage
4.4.2. Information on Designations Awarded
4.4.3. Other Therapeutic Indications under Evaluation
4.5. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Contributions from Academia
4.6. Stem Cell Therapies for Stroke

5. UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs Analysis in Stem Cell Therapies for Cardiovascular and Metabolic Disorders Market
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights: Cardiovascular Disorders
5.2.1.3. Key Insights: Metabolic Disorders
5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.2.2.1. Unmet Needs by Type of Indication
5.2.2.2.2. Unmet Needs by Stem Cell Lineage
5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights: Cardiovascular Disorders
5.2.3.3. Key Insights: Metabolic Disorders
5.2.4. Expert Opinions
5.2.4.1. Cardiovascular Disorders
5.2.4.1.1. Charles E Murry, Institute for Stem Cell and Regenerative Medicine
5.2.4.1.2. Stuart Conolly, McMaster University
5.2.4.1.3. Akshay Desai, Harvard Medical School; Sheryl Chow, Western University of Health Sciences College of Pharmacy; Scott Solomon, Harvard Medical School; Orly Vardeny, William S. Middleton Memorial VA Hospital
5.2.4.1.4. Naser M Ammash, Mayo Clinic and Joseph A Dearani, Mayo Clinic
5.2.4.1.5. Julie Anne Mitchell, Heart Foundation
5.2.4.1.6. Andre Terzic, Mayo Clinic and Atta Behfar, Mayo Clinic
5.2.4.2. Metabolic Disorders
5.2.4.2.1. Heather A Lau, Lysosomal Storage Disease Program, NYU Langone
5.2.4.2.2. Larry Hirsch, BD Diabetes Care
5.2.4.2.3. Michael Hirst, International Diabetes Federation; David Strain, University of Exeter Medical School in the UK; Xavier Cos, Sant Marti de Provenals Primary Care Centres
5.2.5. Summary of Key Unmet Needs in Cardiovascular and Metabolic Disorders

6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Cardiovascular Disorders
6.2.1. Heart Failure
6.2.2. Myocardial Infarction
6.2.3. Critical Limb Ischemia
6.2.3.4. Stem Cell Therapies for Critical Limb Ischemia
6.3. Metabolic Disorders
6.3.1. Diabetes
6.3.1.1. Overview
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Landscape
6.3.1.4. Stem Cell Therapies for Diabetes

7. COMPANY COMPETITIVENESS ANALYSIS
7.1 Chapter Overview
7.2 Methodology
7.3 Assumptions and Key Parameters
7.4 Competitiveness Analysis
7.4.1. Companies Developing Stem Cell Therapies for Cardiovascular Disorders
7.5.1. Company Developing Stem Cell Therapies for Metabolic Disorders

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnerships
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Therapeutic Area
8.3.4. Regional Analysis
8.3.5. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Type of Stem Cells
9.3.6. Most Active Players
9.3.7. Most Active Investors
9.4. Concluding Remarks

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Publications
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Key Journals
10.3.3. Analysis by Type of Study
10.3.4. Analysis by Type of Disorder
10.3.4.1. Cardiovascular Disorders
10.3.4.2. Metabolic Disorders
10.3.5. Analysis by Stem Cell Lineage
10.3.6. Analysis by Stem Cell Lineage and Focused Indication
10.3.7. Emerging Areas of Focus

11. STEM CELL THERAPIES FOR CARDIOVASCULAR DISORDERS: THERAPY PROFILES
11.1. Chapter Overview
11.2. Stempeucel (Stempeutics Research)
11.3. Autologous Bone Marrow Concentrate (aBMC) (Cesca Therapeutics)
11.4. BCDA-01 (BioCardia)
11.5. BCDA-02 (BioCardia)
11.6. CLBS14-NORDA (Caladrius Biosciences)
11.7. MPC-150-IM (Mesoblast)
11.8. PLX-PAD (Pluristem Therapeutics)

12. STEM CELL THERAPIES FOR METABOLIC DISORDERS: THERAPY PROFILES
12.1. Chapter Overview
12.2. Strimvelis (Orchard Therapeutics)
12.3. OTL-200 (Orchard Therapeutics)
12.4. Stem Cell Therapy (Global Cell Med)
12.5. LMSCs (Longeveron)
12.6. Stem Cell Educator Therapy (Tianhe Stem Cell Biotechnologies)

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders, 2019-2030
13.3.1. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030
13.3.2. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.3.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030
13.4. Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030
13.4.1. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030
13.4.2. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030
13.4.3. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030
13.4.4. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030
13.4.5. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030
13.4.6. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030
13.4.7. Stem Cell Therapies Market for Cardiovascular Disorders: Myocardial Infarction, 2019-2030
13.4.7.1. Target Patient Population
13.4.7.2. Cellgram-AMI (Pharmicell)
13.4.7.3. Cardiocell (Cytopeutics)
13.4.8. Stem Cell Therapies Market for Cardiovascular Disorders: Heart Failure, 2019-2030
13.4.8.1. Target Patient Population
13.4.8.2. HeartSheet (Terumo BCT)
13.4.8.3. BCDA-01 (BioCardia)
13.4.8.4. MPC-150-IM (Mesoblast)
13.4.8.5. Cardiocell (Cytopeutics)
13.4.8.6. MyoCell (U.S. Stem Cell)
13.4.9. Stem Cell Therapies Market for Cardiovascular Disorders: Critical Limb Ischemia, 2019-2030
13.4.9.1. Target Patient Population
13.4.9.2. Stempeucel (Stempeutics Research)
13.4.9.3. aBMC (Cesca Therapeutics)
13.4.9.4. PLX-PAD (Pluristem Therapeutics)
13.4.9.5. Cardiocell (Cytopeutics)
13.4.10. Stem Cell Therapies Market for Cardiovascular Disorders: Other Indications, 2019-2030
13.4.10.1. Target Patient Population
13.4.10.2. BCDA-02 (BioCardia)
13.4.10.3. CLBS14-NORDA (Caladrius Biosciences )
13.4.10.4. Cardiocell (Cardiocell)
13.5. Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030
13.5.1. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030
13.5.2. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.5.3. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030
13.5.4. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030
13.5.5. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cell Lineage, 2019-2030
13.5.6. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030
13.5.7. Stem Cell Therapies Market for Metabolic Disorders: ADA-SCID, 2019-2030
13.5.7.1. Target Patient Population
13.5.7.2. Strimvelis (Orchard Therapeutics)
13.5.8. Stem Cell Therapies Market for Metabolic Disorders: Metachromatic Leukodystrophy, 2019-2030
13.5.8.1. Target Patient Population
13.5.8.2. OTL-200 (Orchard Therapeutics)
13.5.9. Stem Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, 2019-2030
13.5.9.1. Target Patient Population
13.5.9.2. Unnamed Stem Cell Therapy by Global Cell Med

14. CONCLUSION
14.1. The Treatment Landscape of Cardiovascular and Metabolic Disorders is Characterized by Several Unmet Needs; Stem Cell Therapies have Demonstrated the Potential to Offer Viable and Lasting Therapeutic Effect
14.2. The Market Features a Promising Pipeline with Several Mid and Late Stage Product Therapies, which are Mostly based on Stem Cells Derived from Adults
14.3. The Fragmented Developer Landscape Includes Small, Mid-Sized and Established Players; the Majority of Stakeholders are Presently based in North America and Europe
14.4. The Heightened Pace of Research in this Field is Evident in Multiple R&D Agreements Inked and the Rise in Number of Scientific Articles Published in the Recent Years
14.5. Development Efforts in this Field have Garnered the Attention of Various Private and Public Investors, Resulting in Significant Capital Investments, which are Likely to Provide the Necessary Boost to the Market's Future Growth
14.6. Given the Impending Approval of Multiple Late Stage Molecules, the Market is Poised to Grow at a Significant Pace in the Coming Years

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Kadimastem
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager
15.3. Xcelthera
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Xuejun H Parsons, Chief Executive Officer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/qmw95h

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Stem Cells